Opening with a quote from New York Gov. Andrew Cuomo:
“We were thinking that maybe we were going to find a higher percentage of essential employees who were getting sick because they were going to work—that these may be nurses, doctors, transit workers. That’s not the case,†he said. “They’re not working, they’re not traveling, they’re predominantly downstate, predominantly minority, predominantly older.â€
the editors of the Wall Street Journal continue with some pertinent observations:
More investigation is needed, but the virus may be spreading mostly within multigenerational households or public housing. Collecting more information about infected individuals’ habits would have been especially useful early in the pandemic before most businesses were shut down. This data could reveal patterns that suggest the most likely venues for transmission.
New York Mayor Bill de Blasio said the city will start collecting employment and demographic information as part of its antibody tests to pin down how the virus has spread. Mr. Cuomo this month released final results from a random antibody test of 15,000 people across the state, which raised some questions that need to be further investigated.
For instance, estimated infections are 10 percentage points higher in the Bronx than Manhattan, which is more dense. Latinos were also more than twice as likely to have antibodies than Asians. Low-income folks are more likely to work in jobs interfacing with customers, but other behavioral differences may account for their antibody disparities.
Surprisingly, millennials who are known to crowd bars and clubs were about as likely to carry antibodies as baby boomers. Even more curious, 12% of health-care workers tested positive for antibodies compared to 20% of the general population. This is good news since it suggests that the virus isn’t mainly being spread via the health-care system. Surveying more people through antibody and diagnostic tests could help experts better identify the major transmission vehicles.
Scientists often use such observational studies to identify risk factors for diseases when they can’t do randomized experiments. Regression analysis can help discern the variables that most influence an outcome while controlling for others. While studies can’t control for all confounding variables, they can still show important patterns.
Incorporating such surveys in random population tests could also let states reopen more safely. People could be asked how often each week they take mass transit, dine out, use a gym or visit a salon. Those who test positive could be compared to those who test negative, controlling for other factors.
This is of much more than merely academic interest. The measures that have been taken to slow the increase in COVID-19 cases including social distancing, “stay at home” directives, closing of public facilities like parks, and face mask directives, are all guesses. Sometimes they’re informed guesses; sometimes less so. It’s important to know whether sitting in a restaurant with other diners puts you at risk. It’s important to instill confidence in the public and it’s important to the restaurant—it may determine whether the enterprise remains viable. Theoretically, there may be a risk but in practice the risk may be so low as to be negligible. As Yogi Berra put it, in theory there’s no difference between practice and theory but in practice there is.
If we want to pinpoint answers perfectly to cause and effect, we will be paralyzed in place for a very long time. In previous episodes of containing a virus our responses were moderated, with a fair amount of trial and error in play. There were no daily death tallies reported, no business lockdowns, no violation of rights, and somehow we survived and got past said medical crisis without crashing and destroying so many individual lifestyles, livelihoods and enjoyed customs.
Pinpoint answers are what we need to move from “broad” mitigations like lockdowns to “targeted” mitigations that would be permit 95-99% of society to resume.
The issue for the US is it is weak at decision makers working with scientists/experts to *quickly* and *systematically* gather data and coordinate a response to the data. That is true at all levels (Federal, State).
Contrast with the Germans, who are strong at this. Here is a epidemiological study they performed on a hotspot. You can bet that study was fed back to decision making weeks ago.
https://www.ukbonn.de/C12582D3002FD21D/vwLookupDownloads/Streeck_et_al_Infection_fatality_rate_of_SARS_CoV_2_infection2.pdf/%24FILE/Streeck_et_al_Infection_fatality_rate_of_SARS_CoV_2_infection2.pdf
The issue is one of trust. The Germans are very process-oriented and they trust the process. We trust almost no one and, generally, with good reason.
“The issue for the US is it is weak at decision makers working with scientists/experts to *quickly* and *systematically* gather data and coordinate a response to the data. ”
We responded pretty quickly to Ebola and adapted our responses quickly. We didnt really see SARS or MERS. Other than that we have pretty much just had the flu, and we know how to make vaccines for those. So I suspect this is more than just trusting the process. It means that we need to have right people in place making the right decisions. We have not had enough of that in the US, especially in the critical early period. That is where the successful countries like Germany, Greece, Australia and New Zealand excelled.
Steve
which over the last 10 seasons has varied in effectiveness from 19% to 52%. Thought experiment: would a vaccine with 19% effectiveness have been enough to avoid the “stay at home” directives and lockdowns? I don’t think so.
“would a vaccine with 19% effectiveness”
You how it works right? We now use quadrivalent vaccines, meaning that we try to predict, educated guess, which strains of the flu will be prevalent in the coming season. So they prepare the vaccine against two A strains and two B strains. If we had a particularly virulent strain and we were concerned about it coming back we wouldn’t have to guess.
https://www.cdc.gov/flu/prevent/quadrivalent.htm
Steve
How can one make any positive conclusion about the Obama administration’s handling about Ebola?
(a). Despite a complaints about inadequate PPE; the national stockpile was not replenished.
(b). The number of cases increased 10x fold over 3 months yet there were no border restrictions put in place until someone sick deliberately traveled to the US
Where is the successful linkage between data gathering to policy implementation?
a) It was not replenished after the Ebola outbreak was over. The admin designated centers to take care of Ebola and made sure those places had lots of PPE so they wouldnt face what we face now. With a struggling economy neither the Obama admin nor the Congress prioritized replenishment. Certainly no reason it shouldn’t have ben addressed when the economy got better, especially when the economy for the last 3 years is the best in the history of the world.
b) We had a total of 11 cases in the US. 2 of those were contracted in the US. The science was followed and we had few cases and Ebbola was quickly controlled in the US. Compare that with what the critics wanted. They didnt want to let US citizens return to the US if they MIGHT have Ebola. (Ironic that with Covid the critics didnt follow their own criticisms of Obama isn’t it?) They wanted to stop all travel directly and indirectly from Africa. They wanted quarantine camps. IOW they wanted significant economic disruption which the science suggested was not merited, which ended up being correct.
Where we were slow was in forming ands sending a response over to Africa.
https://www.vox.com/2020/2/26/21154253/trump-ebola-tweets-coronavirus
Steve
That response confuses me, steve. In previous comments you’ve taken the position that the Trump economy was just a continuation of the Obama economy and yet here you’re saying that the U. S. economy was struggling in 2016. That’s when the replenishment would have taken place. Could you elaborate on your view that the U. S. economy was struggling in 2016?
I am being sarcastic. Sorry. After countless hours reading conservatives complain that the economy was so horrible under Obama and how it is the best ever in the history of the world (that is Trump’s actual claim by the way) with Trump, it is hard not to poke at them a bit.
Steve
By this measure; Trump has until 2022 to solve the PPE shortages.
??? We had no shortages fighting H1N1 or Ebola. Why cant Trump meet that standard?
Steve
Lets see?
H1N1 Obama decided on a herd immunity strategy. And Ebola by grace had only 11 cases in the US (and it was pure luck, the CDC permitted one of the domestic cases to board a plane).
I don’t know if I would say there were enough PPE during Ebola. More accurate to say they noticed more PPE usage but they did not run out. Then they did not bother to refill the national stockpile that they used up.
That’s not being responsive to data; its being lucky and spending down an inheritance.
” And Ebola by grace had only 11 cases in the US (and it was pure luck, the CDC permitted one of the domestic cases to board a plane).”
You mean the one they transferred? And, you missed my point. The opposition, provided the link to Trump’s statements, wanted to shut down air travel and out people in camps. Refuse to allow Americans with Ebola back in the US. Instead we followed the science. Outbreak controlled (element of luck probably) but the response was not harmful to everyone else needlessly.
Herd immunity for H1N1? Well, link goes to contemporaneous piece publicizing the approval of 4 different vaccines. (They had asked 5 different companies to make vaccines.) If you were relying on herd immunity why order vaccines? Are you sure you mean herd immunity?
Anyway, for whatever reason (i dont remember) the growth of the vaccines fro H1N1 was much slower than for normal flu vaccines so we did end up with shortages. For that I guess it would be fair to blame the Obama admin fo onto foreseeing that and placing orders with 7 or 8 companies.
https://www.cidrap.umn.edu/news-perspective/2009/09/fda-approves-four-companies-h1n1-vaccines
Steve